Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases
暂无分享,去创建一个
[1] C. Sticht,et al. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms , 2020, Histopathology.
[2] S. Koschmieder,et al. Role of inflammation in the biology of myeloproliferative neoplasms. , 2020, Blood reviews.
[3] G. Bohra,et al. Focal segmental glomerulosclerosis in a patient with prefibrotic primary myelofibrosis , 2018, BMJ Case Reports.
[4] D. Jo,et al. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study , 2017, The Korean journal of internal medicine.
[5] J. Aniort,et al. Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] G. Barbatelli,et al. Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era , 2017, Clinical nephrology. Case studies.
[7] G. Barbatelli,et al. WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era. , 2017, Clinical nephrology.
[8] A. Dueck,et al. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development , 2015, Mediators of inflammation.
[9] S. Verstovsek,et al. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib , 2015, BMC Nephrology.
[10] H. Hasselbalch,et al. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. , 2014, Leukemia research.
[11] J. Bay,et al. [The myeloproliferative neoplasms-related glomerulopathy]. , 2014, La Revue de medecine interne.
[12] K. Hatta,et al. Renal biopsy cases in myeloproliferative neoplasms (MPN) , 2013, CEN Case Reports.
[13] T. Robak,et al. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. , 2013, Current Medicinal Chemistry.
[14] V. D’Agati,et al. Myeloproliferative neoplasms cause glomerulopathy. , 2011, Kidney international.
[15] F. Cakalagaoglu,et al. Focal Segmental Glomerulosclerosis Associated with Idiopathic Myelofibrosis , 2010, Renal failure.
[16] C. Alpers,et al. A new look at platelet-derived growth factor in renal disease. , 2008, Journal of the American Society of Nephrology : JASN.
[17] Nong Zhang,et al. Aldose reductase regulates TGF‐β1‐induced production of fibronectin and type IV collagen in cultured rat mesangial cells , 2006, Nephrology.
[18] T. Kondo,et al. Focal segmental glomerulosclerosis associated with essential thrombocythemia , 2006, Clinical and Experimental Nephrology.
[19] K. Chan,et al. Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] M. Martyré. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. , 1995, Leukemia & lymphoma.
[21] M. Perazella,et al. Nephrotic syndrome associated with agnogenic myeloid metaplasia. , 1994, American journal of nephrology.
[22] G. Striker,et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. Gown,et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Bryckaert,et al. Increased intraplatelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasia , 1991, British journal of haematology.
[25] E. Ruoslahti,et al. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.